A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice

• Published in: Cancer research (Chicago, Ill.) Vol. 54; no. 17; pp. 4576 - 4579
• Main Authors: OLSON, K. A, FRENCH, T. C, VALLEE, B. L, FETT, J. W
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.09.1994
• Subjects: Adenocarcinoma - prevention & control; Animals; Antibodies, Monoclonal - pharmacology; Antineoplastic agents; Biological and medical sciences; Colonic Neoplasms - prevention & control; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Immunoglobulin G - pharmacology; Immunotherapy; Male; Medical sciences; Mice; Mice, Nude; Pharmacology. Drug treatments; Proteins - antagonists & inhibitors; Proteins - immunology; Proteins - pharmacology; Ribonuclease, Pancreatic; Specific Pathogen-Free Organisms; Tumor Cells, Cultured; Antineoplastic agent; Adenocarcinoma; Rodentia; Malignant tumor; Monoclonal antibody; In vitro; Vascularization; Angiogenesis; In vivo; Vertebrata; Experimental disease; Mammalia; Treatment; Mouse; Animal; Immunotherapy; Established cell line; Digestive diseases; Intestinal disease; Colon; Inhibition; Neovascularization; Tumor cell
• ISSN: 0008-5472; 1538-7445

Human angiogenin, a potent inducer of neovascularization, is secreted by HT-29 colon adenocarcinoma cells. microgram doses of a monoclonal antibody that neutralizes the in vitro and in vivo activities of angiogenin prevent or delay the appearance of s.c. HT-29 tumors in athymic mice in a statistically significant, dose-dependent manner. The antibody is not cytotoxic to tumor cells in vitro, which indicates that inhibition of tumor growth most likely occurs by neutralization of the activity of angiogenin in vivo and further implies a critical role for angiogenin in the early development of HT-29 tumors. The results suggest a therapeutically useful approach to the treatment of angiogenin-dependent malignancy.